ABCDEFGHIJKLMNOPQRSTUV
1
organismpre-conditiontermdrugincreased/decreased/neutralphenotypecompared tonegationcuration error?comment
2
655384784CGPatients with the CG genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype.personacute coronary artery syndromeacute coronary syndrome (mesh:68054058)beta blockersincreasedrehospitalizationGG
3
655387011GTPatients with the CG genotype and breast cancer who are treated with cyclophosphamide may have longer disease-free progression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance of disease-free progression.personbreast cancercyclophosphamideincreaseddisease-free progressionTTgenotype mismatch
4
655385221CGPatients with the CG genotype and diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype.persondiabetesmuraglitazarincreasededemaCC
5
655385095CGPatients with the CG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation.personHIVritonavirdecreasedtriglyceride elevationCC
6
655385301CGPatients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype.personrheumatoid arthritismethotrexatedecreasedsymptom improvementGG
7
655384765CGPatients with the CG genotype and rs1801252A who are treated with verapamil: 1)may have an increased risk for treatment failure as compared to patients with the GG genotype 2) may have an increased risk for adverse events as compared to patients with the GG genotype.personrs1891252verapamilincreasedtreatment failure, adverse events GGrsid error
8
655384985CGPatients with the CG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.personschizophreniaolanzapinedecreasedextreme weight gainGG
9
655385100CGPatients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.persondiabetes type 2rosiglitazonedecreasedfasting plasma glucose, 2-hour postprandial glucose, and HbA1cCC
10
655385676CGPatients with the CG genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype.personantipsychoticsantipsychoticsincreasedmetabolic syndromeGG
11
655385031CGPatients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.personwarfarindecreaseddoseGG
12
655384779CGPatients with the CG genotype: 1) may have intermediate metabolism of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype.personthiopurinesincreased toxicityCC
13
655384973CTPatients with the CT genotype were not studied.no statement to convert
14
655384706CTPatients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to troglitazone.personhigh risk of diabetes type 2troglitazoneincreasedbeta cell functionTTbeta call function
15
655384997CTPatients with the CT genotype and bipolar disorder who are treated with lithium may be more likely to have a reduction in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.personbipolar disorderlithiumdecreasedsymptoms TT
16
655387016CTPatients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype.personbreast cancercyclophophamidedecreaseddisease free survivalCCyes
17
655386591CTPatients with the CT genotype and cancer who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the TT genotype.personcancercisplatinincreasedhearing lossTT
18
613979405CTPatients with the CT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype.personcluster headachetriptansdecreasedpain, frequencyCC
19
655385213CTPatients with the CT genotype and diabetes who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.persondiabetes type 2muraglitazar decreasededemaCC
20
655385127CTPatients with the CT genotype and erectile dysfunction who are treated with sildenafilthan may be less likely to have positive erectile response as compared to patients with the TT genotype.personerectile dysfunctionsildenafilthan decreasedpositive erectile responseTT
21
655384864CTPatients with the CT genotype and major depression who are treated with fluvoxamine, paroxetine, or milnacipran may be less likely to respond as compared to patients with the CC genotype.personmajor depressionfluvoxamine or paroxetine or milnaciprandecreasedresponseCC
22
655387944CTPatients with the CT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate may have an increased risk for GI toxicity when treated with methotrexate as compared to patients with the CC genotype.person precursor cell lymphoblastic leukemia-lymphomamethotrexateincreasedGI toxicityCC
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100